Delayed release dosage forms
View Patent ↗A delayed release pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.
1. A delayed release oral solid dosage form comprising:
i) an immediate release core comprising a therapeutically effective amount of a drug which can be absorbed in the colon; from about 5% to about 50% of at least two surfactants by weight of the core, wherein one of the surfactants is polyethylene glycol; and ii) a delayed release material compression coated onto the surface of said core, said delayed release material consisting of a mixture of a heteropolysaccharide gum and a homopolysaccharide gum and iii) a material selected from the group consisting of a monosaccharide selected from the group consisting of dextrose and fructose, a disaccharide selected from the group consisting of sucrose and lactose, a polyhydric alcohol selected from the group consisting of xylitol, sorbitol, and mannitol, microcrystalline cellulose, starches, and any combinations or mixtures thereof; said mixture being compression coated in an amount effective to impart a desired delayed release such that said dosage form provides no release of drug until at least about 2 hours after oral administration of the dosage form, and the inclusion of the surfactant in the core facilitates the release of the drug from the dosage form in less than about 4 hours after initial release; said dosage form providing an in-vitro dissolution rate of the dosage form, when measured by the USP apparatus type III with 250 mL solution (pH 1.5) at 15 dpm that is 0% by weight drug released at about 3 hours, from about 5% to about 40% by weight drug release at about 4 hours, from about 30% to about 90% by weight drug released at 5 hours and greater than about 60% by weight drug released after 6 hours.
2. The delayed release oral solid dosage form of claim 1 , wherein said core is a compressed core.
3. The delayed release oral solid dosage form of claim 1 wherein said core further comprises a disintegrant.
4. The delayed release oral solid dosage form of claim 3 , wherein said core comprises from about 5 to about 20 percent disintegrant, by weight.
5. The delayed release oral solid dosage form of claim 3 , wherein said disintegrant is selected from the group consisting of starch, veegum, crospovidone, cellulose, kaolin, microcrystalline cellulose, crosslinked polyvinyl pyrrolidone, croscarmellose sodium, crospovidone, crosslinked carboxy methyl cellulose, sodium starch glycolate, and mixtures thereof.
6. The delayed release oral solid dosage form of claim 1 , wherein said heteropolysaccharide gum and said homopolysaccharide gum are agglomerated with said second excipient prior to being compression coated onto said core.
7. The delayed release oral solid dosage form of claim 6 , wherein said second excipient is a monosaccharide selected from the group consisting of dextrose and fructose, a disaccharide selected from the group consisting of sucrose, and lactose, a polyhydric alcohol selected form the group consisting of xylitol, sorbitol and mannitol, microcrystalline cellulose, starches and any combinations or mixtures thereof.
8. The delayed release oral dosage form of claim 1 , wherein the delayed release material comprises from about 7.5 to about 50 percent gum from (i), and from about 30 to about 95 percent material from (iii).
9. The delayed release oral solid dosage form of claim 8 , wherein said gums comprise a mixture of xanthan gum and locust bean gum.
10. The delayed release oral solid dosage form of claim 9 , wherein the xanthan gum and locust bean gum are in a ratio of about 1:3 to about 3:1.
11. The delayed release oral solid dosage form of claim 1 , wherein the drug is selected from the group consisting of an antidiarrheal, an antibiotic, an immunomodulators, an aminosalicylates, an immunosuppressive agent, an anti-tumor necrosis factor substance, a glucorticoid, polypeptides, and proteins, and combinations thereof.
12. The delayed release oral solid dosage form of claim 1 , wherein the drug is delivered to provide a local therapeutic effect.
13. The delayed release oral solid dosage form of claim 1 , wherein the drug is delivered to provide a systemic therapeutic effect.
14. The delayed release oral solid dosage form of claim 1 , wherein the drug is delivered to provide a local and systemic therapeutic effect.
15. The delayed release oral solid dosage form of claim 1 , wherein said dosage form provides an in vitro dissolution rate, when measured by the USP apparatus Type III, with 250 ml solution pH 1.5 at 15 dpm that is 0% by weight drug released at about 3 hours, from about 10% to about 40% by weight drug release at about 4 hours, from about 60% to about 90% by weight drug released at 5 hours and greater than about 85% by weight drug released after 6 hours.
16. The delayed release dosage form of claim 1 , wherein said dosage form does not have an intermediate coating between the compression coating and the core.
17. The delayed release oral solid dosage form of claim 1 , wherein said gums comprise a mixture of xanthan gum and locust bean gum.